Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07150806 · ClinicalTrials.gov registry record · Phase 1
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
A Phase 1 study of Recurrent Meningioma, sponsored by Joshua Palmer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07150806 is a Phase 1 study of Recurrent Meningioma that is actively recruiting participants, run by Joshua Palmer. The registered enrollment target is 30 participants, below the 48-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07150806, a Phase 1 study of Recurrent Meningioma, is actively recruiting participants, sponsored by Joshua Palmer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Echocardiography Test
- RADIATION Gallium Ga 68-DOTATATE
- DRUG Actinium Ac 225 DOTATATE RYZ101
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07150806
The ClinicalTrials.gov registry entry for NCT07150806 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (37% lower). The listed sponsor is Joshua Palmer, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Meningioma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07150806 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07150806 about?
NCT07150806 is a clinical study titled "RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma". This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive dr...
What is the current status of trial NCT07150806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-11-12. Estimated completion is 2026-12-31.
What conditions does trial NCT07150806 study?
This clinical trial studies the following conditions: Recurrent Meningioma.
What interventions are being tested in trial NCT07150806?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Echocardiography Test (PROCEDURE), Gallium Ga 68-DOTATATE (RADIATION), Actinium Ac 225 DOTATATE RYZ101 (DRUG).
Who is sponsoring clinical trial NCT07150806?
This trial is sponsored by Joshua Palmer, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07150806 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
ACTIVE NOT RECRUITING · Phase 1
-
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
RECRUITING · Phase 2
-
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
RECRUITING · Phase 2
-
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
RECRUITING · Phase 2
-
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
RECRUITING · Phase 2
-
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.